REQUIP XL

Requip Xl Adverse Events Reported to the FDA Over Time

How are Requip Xl adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Requip Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Requip Xl is flagged as the suspect drug causing the adverse event.

Most Common Requip Xl Adverse Events Reported to the FDA

What are the most common Requip Xl adverse events reported to the FDA?

Drug Ineffective	73 (4.04%)
Somnolence	64 (3.54%)
Insomnia	49 (2.71%)
Nausea	49 (2.71%)
Hallucination	35 (1.93%)
Tremor	35 (1.93%)
Dyskinesia	32 (1.77%)
Dizziness	31 (1.71%)
Fatigue	30 (1.66%)
Oedema Peripheral	29 (1.6%)
Medication Residue	26 (1.44%)
	Show More
Asthenia	24 (1.33%)
Malaise	21 (1.16%)
Obsessive-compulsive Disorder	21 (1.16%)
Ill-defined Disorder	20 (1.11%)
Restless Legs Syndrome	20 (1.11%)
Headache	19 (1.05%)
Withdrawal Syndrome	19 (1.05%)
Fall	18 (1%)
Muscle Spasms	18 (1%)
Pain	16 (.88%)
Feeling Abnormal	15 (.83%)
Product Quality Issue	15 (.83%)
Sleep Disorder	15 (.83%)
Drug Administration Error	14 (.77%)
Aggression	13 (.72%)
Balance Disorder	13 (.72%)
Dementia	13 (.72%)
Joint Swelling	13 (.72%)
Loss Of Consciousness	13 (.72%)
Overdose	13 (.72%)
Confusional State	12 (.66%)
Psychotic Disorder	12 (.66%)
Movement Disorder	11 (.61%)
Musculoskeletal Stiffness	11 (.61%)
Paranoia	11 (.61%)
Parkinsonism	11 (.61%)
Sudden Onset Of Sleep	11 (.61%)
Abasia	10 (.55%)
Drug Effect Decreased	10 (.55%)
Gait Disturbance	10 (.55%)
Immobile	10 (.55%)
Pain In Extremity	10 (.55%)
Palpitations	10 (.55%)
Anxiety	9 (.5%)
Drug Interaction	9 (.5%)
Hallucination, Visual	9 (.5%)
Hypersexuality	9 (.5%)
Libido Increased	9 (.5%)
Muscular Weakness	9 (.5%)
Orthostatic Hypotension	9 (.5%)
Restlessness	9 (.5%)
Vomiting	9 (.5%)
Abdominal Discomfort	8 (.44%)
Abnormal Behaviour	8 (.44%)
Blood Pressure Decreased	8 (.44%)
Depression	8 (.44%)
Hyperhidrosis	8 (.44%)
Personality Change	8 (.44%)
Arthralgia	7 (.39%)
Constipation	7 (.39%)
Dependence	7 (.39%)
Diarrhoea	7 (.39%)
Disturbance In Sexual Arousal	7 (.39%)
Dysgraphia	7 (.39%)
Dyspnoea	7 (.39%)
Hypoaesthesia	7 (.39%)
Middle Insomnia	7 (.39%)
Off Label Use	7 (.39%)
Adverse Drug Reaction	6 (.33%)
Death	6 (.33%)
Drug Effect Delayed	6 (.33%)
Gambling	6 (.33%)
Impulse-control Disorder	6 (.33%)
Mental Disorder	6 (.33%)
Mobility Decreased	6 (.33%)
Myocardial Infarction	6 (.33%)
Nervousness	6 (.33%)
On And Off Phenomenon	6 (.33%)
Panic Attack	6 (.33%)
Pneumonia	6 (.33%)
Suicidal Ideation	6 (.33%)
Swelling	6 (.33%)
Therapeutic Response Decreased	6 (.33%)
Therapeutic Response Unexpected	6 (.33%)
Transient Ischaemic Attack	6 (.33%)
Back Pain	5 (.28%)
Blood Pressure Increased	5 (.28%)
Compulsive Shopping	5 (.28%)
Erythema	5 (.28%)
Excessive Sexual Fantasies	5 (.28%)
Inappropriate Schedule Of Drug Admi...	5 (.28%)
Initial Insomnia	5 (.28%)
Intentional Overdose	5 (.28%)
Mania	5 (.28%)
Pathological Gambling	5 (.28%)
Weight Decreased	5 (.28%)
Abdominal Pain Upper	4 (.22%)
Agitation	4 (.22%)
Alopecia	4 (.22%)
Arthropathy	4 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Requip Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Requip Xl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Requip Xl

What are the most common Requip Xl adverse events reported to the FDA?

Neurological	189 (10.45%)
Therapeutic And Nontherapeutic Effe...	127 (7.02%)
Movement Disorders	116 (6.41%)
Sleep Disorders	82 (4.53%)
Gastrointestinal Signs	79 (4.37%)
Disturbances In Thinking	55 (3.04%)
Anxiety Disorders	54 (2.99%)
Medication Errors	49 (2.71%)
Musculoskeletal And Connective Tiss...	44 (2.43%)
Product Quality Issues	43 (2.38%)
Injuries	37 (2.05%)
	Show More
Sexual Dysfunctions, Disturbances A...	36 (1.99%)
Muscle	35 (1.93%)
Psychiatric	35 (1.93%)
Personality Disorders	34 (1.88%)
Joint	29 (1.6%)
Mental Impairment	28 (1.55%)
Epidermal And Dermal Conditions	24 (1.33%)
Lifestyle Issues	23 (1.27%)
Cardiac And Vascular Investigations	20 (1.11%)
Headaches	20 (1.11%)
Infections - Pathogen Unspecified	19 (1.05%)
Respiratory	19 (1.05%)
Impulse Control	18 (1%)
Gastrointestinal Motility And Defec...	17 (.94%)
Decreased And Nonspecific Blood Pre...	16 (.88%)
Skin Appendage Conditions	16 (.88%)
Cardiac Arrhythmias	15 (.83%)
Suicidal And Self-injurious Behavio...	15 (.83%)
Deliria	13 (.72%)
Schizophrenia And Other Psychotic	13 (.72%)
Sleep Disturbances	13 (.72%)
Cardiac Disorder Signs	11 (.61%)
Depressed Mood Disorders	10 (.55%)
Psychiatric And Behavioural Symptom...	10 (.55%)
Changes In Physical Activity	9 (.5%)
Physical Examination Topics	9 (.5%)
Electrolyte And Fluid Balance Condi...	8 (.44%)
Renal And Urinary Tract Investigati...	8 (.44%)
Therapeutic Procedures And Supporti...	8 (.44%)
Mood Disorders	7 (.39%)
Neuromuscular	7 (.39%)
Urinary Tract Signs	7 (.39%)
Central Nervous System Vascular	6 (.33%)
Coronary Artery	6 (.33%)
Fatal Outcomes	6 (.33%)
Hepatobiliary	6 (.33%)
Pulmonary Vascular	6 (.33%)
Bone And Joint Injuries	5 (.28%)
Legal Issues	5 (.28%)
Manic And Bipolar Mood Disorders	5 (.28%)
Salivary Gland Conditions	5 (.28%)
Communication Disorders	4 (.22%)
Family Issues	4 (.22%)
Heart Failures	4 (.22%)
Vision	4 (.22%)
Vulvovaginal Disorders	4 (.22%)
Body Temperature Conditions	3 (.17%)
Dissociative	3 (.17%)
Endocrine Investigations	3 (.17%)
Gastrointestinal Inflammatory Condi...	3 (.17%)
Gender Related Factors	3 (.17%)
Musculoskeletal And Connective Tiss...	3 (.17%)
Penile And Scrotal Disorders	3 (.17%)
Sexual Function And Fertility	3 (.17%)
Tongue Conditions	3 (.17%)
Viral Infectious	3 (.17%)
Abortions And Stillbirth	2 (.11%)
Appetite And General Nutritional	2 (.11%)
Bacterial Infectious	2 (.11%)
Bladder And Bladder Neck Disorders	2 (.11%)
Breast	2 (.11%)
Economic And Housing Issues	2 (.11%)
Eye	2 (.11%)
Gallbladder	2 (.11%)
Gastrointestinal	2 (.11%)
Gastrointestinal Hemorrhages	2 (.11%)
Gastrointestinal Neoplasms Malignan...	2 (.11%)
Genitourinary Tract	2 (.11%)
Hematology Investigations	2 (.11%)
Immunology And Allergy	2 (.11%)
Inner Ear And Viiith Cranial Nerve	2 (.11%)
Investigations, Imaging And Histopa...	2 (.11%)
Metabolic, Nutritional And Blood Ga...	2 (.11%)
Miscellaneous And Site Unspecified ...	2 (.11%)
Oral Soft Tissue Conditions	2 (.11%)
Renal Disorders	2 (.11%)
Skin And Subcutaneous Tissue	2 (.11%)
Upper Respiratory Tract Disorders	2 (.11%)
White Blood Cell	2 (.11%)
Allergic Conditions	1 (.06%)
Angiedema And Urticaria	1 (.06%)
Anterior Eye Structural Change, Dep...	1 (.06%)
Bone Disorders	1 (.06%)
Cardiac Therapeutic Procedures	1 (.06%)
Eating Disorders	1 (.06%)
Enzyme	1 (.06%)
Gastrointestinal Conditions	1 (.06%)
Hearing	1 (.06%)
Lower Respiratory Tract Disorders	1 (.06%)
Nervous System, Skull And Spine The...	1 (.06%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Requip Xl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Requip Xl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.